간편결제 가능보고서 주문 후, 연도 업데이트와 커스터마이징을 위해 당사에서 연락드릴 예정입니다.
상세 사항에 따라 가격이 변동될 수 있으니 참고 바랍니다.
기본 보고서는 영문으로 작성되며, PDF,PPT,DOCX(워드) 형식으로 제공 가능합니다.
보고서 전달 후에는 환불이 불가능하오니 양해 바랍니다.
평균 납기는 2주이며, 형식과 내용에 따라 달라질 수 있습니다.
요약
신경 퇴행성 질환 시장. 신경 퇴행성 질병 시장 개요 신경 퇴행성 질환 시장 규모는 2027 년까지 49,218 백만 달러에 이르는 것으로 추정됩니다. 또한 2022-2027 년 예측 기간 동안 CAGR 3.9%로 성장할 준비가되어 있습니다
Summary
Neurodegenerative Disease Market. Neurodegenerative Disease Market Overview The Neurodegenerative Disease Market size is estimated to reach $49,218 million by 2027. Furthermore, it is poised to grow at a CAGR of 3.9% over the forecast period of 2022-2027
Table of Contents
1. Neurodegenerative Disease Market Overview
1.1 Definitions and Scope
2. Neurodegenerative Disease Market - Executive Summary
3. Neurodegenerative Disease Market – Market Landscape
3.1 Comparative Analysis
3.1.1 Company Benchmarking- Key Companies
3.1.2 Key Financial Analysis
3.1.3 Market Share Analysis
3.1.4 Patent Analysis
3.1.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Neurodegenerative Disease Market - Market Forces
4.1 Market Drivers
4.2 Market Constraints/Challenges
4.3 Porters five force model
4.3.1 Bargaining power of suppliers
4.3.2 Bargaining powers of customers
4.3.3 Threat of new entrants
4.3.4 Rivalry among existing players
4.3.5 Threat of substitutes
5. Neurodegenerative Disease Market – By Strategic Analysis
5.1 Value Chain Analysis
5.2 Opportunities Analysis
5.3 Market Life Cycle Analysis
6. Neurodegenerative Disease Market– By Drug Class (Market Size –$Million/$Billion)
6.1 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
6.2 Acetylcholinesterase (AChE) Inhibitors
6.3 Dopamine Agonists and Antagonist
6.4 Monoamine Oxidase B (MAO-B) Inhibitor
6.5 Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
6.6 Catechol-O-Methyltransferase (COMT) Inhibitor
6.7 Immunomodulators
6.8 Gene Therapy
6.9 Other
7. Neurodegenerative Disease Market– By Indications (Market Size –$Million/$Billion)
7.1 Parkinson’s Disease
7.2 Huntington Disease
7.3 Alzheimer’s Disease
7.4 Amyotrophic Lateral Sclerosis
7.5 Multiple Sclerosis
7.6 Spinal Muscular Atrophy (SMA)
7.7 Others
8. Neurodegenerative Disease Market- By Geography (Market Size -$Million/Billion)
8.1 North America
8.1.1 U.S
8.1.2 Canada
8.1.3 Mexico
8.2 South America
8.2.1 Brazil
8.2.2 Venezuela
8.2.3 Argentina
8.2.4 Ecuador
8.2.5 Peru
8.2.6 Colombia
8.2.7 Costa Rica
8.2.8 Rest of South America
8.3 Europe
8.3.1 U.K
8.3.2 Germany
8.3.3 Italy
8.3.4 France
8.3.5 Netherlands
8.3.6 Belgium
8.3.7 Spain
8.3.8 Denmark
8.3.9 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Australia
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Taiwan
8.4.7 Malaysia
8.4.8 Rest of Asia Pacific
8.5 Rest of World
8.5.1 Middle East
8.5.2 Africa
9. Neurodegenerative Disease Market - Market Entropy
9.1 New service launches
9.2 M&A's, collaborations, JVs and partnerships
10. Neurodegenerative Disease Market- Company Analysis
10.1 Company 1
10.2 Company 2
10.3 Company 3
10.4 Company 4
10.5 Company 5
10.6 Company 6
10.7 Company 7
10.8 Company 8
10.9 Company 9
10.10 Company 10
세금계산서 발행 문의
T. 070 8015 5940
보고서 주문 후, 연도 업데이트와 커스터마이징을 위해 당사에서 연락드릴 예정입니다.
상세 사항에 따라 가격이 변동될 수 있으니 참고 바랍니다.
기본 보고서는 영문으로 작성되며, PDF,PPT,DOCX(워드) 형식으로 제공 가능합니다.
보고서 전달 후에는 환불이 불가능하오니 양해 바랍니다.
평균 납기는 2주이며, 형식과 내용에 따라 달라질 수 있습니다.
요약
신경 퇴행성 질환 시장. 신경 퇴행성 질병 시장 개요 신경 퇴행성 질환 시장 규모는 2027 년까지 49,218 백만 달러에 이르는 것으로 추정됩니다. 또한 2022-2027 년 예측 기간 동안 CAGR 3.9%로 성장할 준비가되어 있습니다
Summary
Neurodegenerative Disease Market. Neurodegenerative Disease Market Overview The Neurodegenerative Disease Market size is estimated to reach $49,218 million by 2027. Furthermore, it is poised to grow at a CAGR of 3.9% over the forecast period of 2022-2027
Table of Contents
1. Neurodegenerative Disease Market Overview
1.1 Definitions and Scope
2. Neurodegenerative Disease Market - Executive Summary
3. Neurodegenerative Disease Market – Market Landscape
3.1 Comparative Analysis
3.1.1 Company Benchmarking- Key Companies
3.1.2 Key Financial Analysis
3.1.3 Market Share Analysis
3.1.4 Patent Analysis
3.1.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Neurodegenerative Disease Market - Market Forces
4.1 Market Drivers
4.2 Market Constraints/Challenges
4.3 Porters five force model
4.3.1 Bargaining power of suppliers
4.3.2 Bargaining powers of customers
4.3.3 Threat of new entrants
4.3.4 Rivalry among existing players
4.3.5 Threat of substitutes
5. Neurodegenerative Disease Market – By Strategic Analysis
5.1 Value Chain Analysis
5.2 Opportunities Analysis
5.3 Market Life Cycle Analysis
6. Neurodegenerative Disease Market– By Drug Class (Market Size –$Million/$Billion)
6.1 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
6.2 Acetylcholinesterase (AChE) Inhibitors
6.3 Dopamine Agonists and Antagonist
6.4 Monoamine Oxidase B (MAO-B) Inhibitor
6.5 Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
6.6 Catechol-O-Methyltransferase (COMT) Inhibitor
6.7 Immunomodulators
6.8 Gene Therapy
6.9 Other
7. Neurodegenerative Disease Market– By Indications (Market Size –$Million/$Billion)
7.1 Parkinson’s Disease
7.2 Huntington Disease
7.3 Alzheimer’s Disease
7.4 Amyotrophic Lateral Sclerosis
7.5 Multiple Sclerosis
7.6 Spinal Muscular Atrophy (SMA)
7.7 Others
8. Neurodegenerative Disease Market- By Geography (Market Size -$Million/Billion)
8.1 North America
8.1.1 U.S
8.1.2 Canada
8.1.3 Mexico
8.2 South America
8.2.1 Brazil
8.2.2 Venezuela
8.2.3 Argentina
8.2.4 Ecuador
8.2.5 Peru
8.2.6 Colombia
8.2.7 Costa Rica
8.2.8 Rest of South America
8.3 Europe
8.3.1 U.K
8.3.2 Germany
8.3.3 Italy
8.3.4 France
8.3.5 Netherlands
8.3.6 Belgium
8.3.7 Spain
8.3.8 Denmark
8.3.9 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Australia
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Taiwan
8.4.7 Malaysia
8.4.8 Rest of Asia Pacific
8.5 Rest of World
8.5.1 Middle East
8.5.2 Africa
9. Neurodegenerative Disease Market - Market Entropy
9.1 New service launches
9.2 M&A's, collaborations, JVs and partnerships
10. Neurodegenerative Disease Market- Company Analysis
10.1 Company 1
10.2 Company 2
10.3 Company 3
10.4 Company 4
10.5 Company 5
10.6 Company 6
10.7 Company 7
10.8 Company 8
10.9 Company 9
10.10 Company 10
